Teva Pharma B.V. withdraws its marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel hydrobromide)

View source ↗

Summary

Teva Pharma B.V. has withdrawn its marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel hydrobromide).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Ischemic Heart Disease
• Stroke
• Thrombosis

Drugs mentioned

• Clopidogrel Teva Pharma (clopidogrel hydrobromide) (clopidogrel hydrobromide)